Tachykinin peptides (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tachykinin peptides" in English language version.

refsWebsite

Global rank English rank

19nih.gov

4^th place

16doi.org

2^nd place

8semanticscholar.org

11^th place

8^th place

4bentham-direct.org

low place

2omim.org

4,380^th place

4,305^th place

bentham-direct.org

Chahl LA (August 2006). "Tachykinins and neuropsychiatric disorders". Curr Drug Targets. 7 (8): 993–1003. doi:10.2174/138945006778019309. PMID 16918327.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (August 2006). "Tachykinins in the respiratory tract". Curr Drug Targets. 7 (8): 1005–10. doi:10.2174/138945006778019318. PMID 16918328.
Improta G, Broccardo M (August 2006). "Tachykinins: role in human gastrointestinal tract physiology and pathology". Curr Drug Targets. 7 (8): 1021–9. doi:10.2174/138945006778019354. PMID 16918330.
Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Curr Drug Targets. 7 (8): 975–92. doi:10.2174/138945006778019381. PMID 16918326.

doi.org

Grace RC, Lynn AM, Cowsik SM (February 2001). "Lipid induced conformation of the tachykinin peptide Kassinin". J. Biomol. Struct. Dyn. 18 (4): 611–21, 623–5. doi:10.1080/07391102.2001.10506693. PMID 11245256. S2CID 42266413.
Carter MS, Krause JE (July 1990). "Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma". J. Neurosci. 10 (7): 2203–14. doi:10.1523/JNEUROSCI.10-07-02203.1990. PMC 6570392. PMID 1695945.
Maggio JE (1988). "Tachykinins". Annu. Rev. Neurosci. 11: 13–28. doi:10.1146/annurev.ne.11.030188.000305. PMID 3284438.
Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ (1990). "Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms". FASEB J. 4 (6): 1606–15. doi:10.1096/fasebj.4.6.1969374. PMID 1969374. S2CID 25935155.
Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (August 1993). "Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior". Physiol. Behav. 54 (2): 249–58. doi:10.1016/0031-9384(93)90107-Q. PMID 7690487. S2CID 33412235.
Duffy RA (May 2004). "Potential therapeutic targets for neurokinin-1 receptor antagonists". Expert Opin Emerg Drugs. 9 (1): 9–21. doi:10.1517/eoed.9.1.9.32956. PMID 15155133.
Salomé N, Stemmelin J, Cohen C, Griebel G (April 2006). "Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils". Pharmacol. Biochem. Behav. 83 (4): 533–9. doi:10.1016/j.pbb.2006.03.013. PMID 16624395. S2CID 15134994.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (March 2008). "Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models". Pharmacol. Biochem. Behav. 89 (1): 36–45. doi:10.1016/j.pbb.2007.10.020. PMID 18045668. S2CID 21490514.
Spooren W, Riemer C, Meltzer H (December 2005). "Opinion: NK3 receptor antagonists: the next generation of antipsychotics?". Nat Rev Drug Discov. 4 (12): 967–75. doi:10.1038/nrd1905. PMID 16341062. S2CID 13270787.
Chahl LA (August 2006). "Tachykinins and neuropsychiatric disorders". Curr Drug Targets. 7 (8): 993–1003. doi:10.2174/138945006778019309. PMID 16918327.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (August 2006). "Tachykinins in the respiratory tract". Curr Drug Targets. 7 (8): 1005–10. doi:10.2174/138945006778019318. PMID 16918328.
Improta G, Broccardo M (August 2006). "Tachykinins: role in human gastrointestinal tract physiology and pathology". Curr Drug Targets. 7 (8): 1021–9. doi:10.2174/138945006778019354. PMID 16918330.
Boot JD, de Haas S, Tarasevych S, et al. (March 2007). "Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma". Am. J. Respir. Crit. Care Med. 175 (5): 450–7. doi:10.1164/rccm.200608-1186OC. PMID 17170385. S2CID 22707433.
Navari RM (December 2007). "Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting". Expert Opin Investig Drugs. 16 (12): 1977–85. doi:10.1517/13543784.16.12.1977. PMID 18042005. S2CID 21437603.
Hickman MA, Cox SR, Mahabir S, et al. (June 2008). "Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats". J. Vet. Pharmacol. Ther. 31 (3): 220–9. doi:10.1111/j.1365-2885.2008.00952.x. PMID 18471143.
Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Curr Drug Targets. 7 (8): 975–92. doi:10.2174/138945006778019381. PMID 16918326.

nih.gov

pubmed.ncbi.nlm.nih.gov

Grace RC, Lynn AM, Cowsik SM (February 2001). "Lipid induced conformation of the tachykinin peptide Kassinin". J. Biomol. Struct. Dyn. 18 (4): 611–21, 623–5. doi:10.1080/07391102.2001.10506693. PMID 11245256. S2CID 42266413.
Carter MS, Krause JE (July 1990). "Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma". J. Neurosci. 10 (7): 2203–14. doi:10.1523/JNEUROSCI.10-07-02203.1990. PMC 6570392. PMID 1695945.
Maggio JE (1988). "Tachykinins". Annu. Rev. Neurosci. 11: 13–28. doi:10.1146/annurev.ne.11.030188.000305. PMID 3284438.
Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ (1990). "Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms". FASEB J. 4 (6): 1606–15. doi:10.1096/fasebj.4.6.1969374. PMID 1969374. S2CID 25935155.
Avanov AIa (1992). "Tachykinins and conformational aspects of their interactions with receptors". Mol. Biol. (Mosk). 26 (1): 5–24. PMID 1324401.
Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (August 1993). "Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior". Physiol. Behav. 54 (2): 249–58. doi:10.1016/0031-9384(93)90107-Q. PMID 7690487. S2CID 33412235.
Alvaro G, Di Fabio R (September 2007). "Neurokinin 1 receptor antagonists--current prospects". Curr Opin Drug Discov Dev. 10 (5): 613–21. PMID 17786860.
Duffy RA (May 2004). "Potential therapeutic targets for neurokinin-1 receptor antagonists". Expert Opin Emerg Drugs. 9 (1): 9–21. doi:10.1517/eoed.9.1.9.32956. PMID 15155133.
Salomé N, Stemmelin J, Cohen C, Griebel G (April 2006). "Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils". Pharmacol. Biochem. Behav. 83 (4): 533–9. doi:10.1016/j.pbb.2006.03.013. PMID 16624395. S2CID 15134994.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (March 2008). "Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models". Pharmacol. Biochem. Behav. 89 (1): 36–45. doi:10.1016/j.pbb.2007.10.020. PMID 18045668. S2CID 21490514.
Spooren W, Riemer C, Meltzer H (December 2005). "Opinion: NK3 receptor antagonists: the next generation of antipsychotics?". Nat Rev Drug Discov. 4 (12): 967–75. doi:10.1038/nrd1905. PMID 16341062. S2CID 13270787.
Chahl LA (August 2006). "Tachykinins and neuropsychiatric disorders". Curr Drug Targets. 7 (8): 993–1003. doi:10.2174/138945006778019309. PMID 16918327.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (August 2006). "Tachykinins in the respiratory tract". Curr Drug Targets. 7 (8): 1005–10. doi:10.2174/138945006778019318. PMID 16918328.
Improta G, Broccardo M (August 2006). "Tachykinins: role in human gastrointestinal tract physiology and pathology". Curr Drug Targets. 7 (8): 1021–9. doi:10.2174/138945006778019354. PMID 16918330.
Boot JD, de Haas S, Tarasevych S, et al. (March 2007). "Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma". Am. J. Respir. Crit. Care Med. 175 (5): 450–7. doi:10.1164/rccm.200608-1186OC. PMID 17170385. S2CID 22707433.
Navari RM (December 2007). "Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting". Expert Opin Investig Drugs. 16 (12): 1977–85. doi:10.1517/13543784.16.12.1977. PMID 18042005. S2CID 21437603.
Hickman MA, Cox SR, Mahabir S, et al. (June 2008). "Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats". J. Vet. Pharmacol. Ther. 31 (3): 220–9. doi:10.1111/j.1365-2885.2008.00952.x. PMID 18471143.
Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Curr Drug Targets. 7 (8): 975–92. doi:10.2174/138945006778019381. PMID 16918326.

ncbi.nlm.nih.gov

Carter MS, Krause JE (July 1990). "Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma". J. Neurosci. 10 (7): 2203–14. doi:10.1523/JNEUROSCI.10-07-02203.1990. PMC 6570392. PMID 1695945.

omim.org

Online Mendelian Inheritance in Man (OMIM): TAC1 - 162320
Online Mendelian Inheritance in Man (OMIM): TAC3 - 162330

semanticscholar.org

api.semanticscholar.org

Grace RC, Lynn AM, Cowsik SM (February 2001). "Lipid induced conformation of the tachykinin peptide Kassinin". J. Biomol. Struct. Dyn. 18 (4): 611–21, 623–5. doi:10.1080/07391102.2001.10506693. PMID 11245256. S2CID 42266413.
Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ (1990). "Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms". FASEB J. 4 (6): 1606–15. doi:10.1096/fasebj.4.6.1969374. PMID 1969374. S2CID 25935155.
Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (August 1993). "Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior". Physiol. Behav. 54 (2): 249–58. doi:10.1016/0031-9384(93)90107-Q. PMID 7690487. S2CID 33412235.
Salomé N, Stemmelin J, Cohen C, Griebel G (April 2006). "Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils". Pharmacol. Biochem. Behav. 83 (4): 533–9. doi:10.1016/j.pbb.2006.03.013. PMID 16624395. S2CID 15134994.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (March 2008). "Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models". Pharmacol. Biochem. Behav. 89 (1): 36–45. doi:10.1016/j.pbb.2007.10.020. PMID 18045668. S2CID 21490514.
Spooren W, Riemer C, Meltzer H (December 2005). "Opinion: NK3 receptor antagonists: the next generation of antipsychotics?". Nat Rev Drug Discov. 4 (12): 967–75. doi:10.1038/nrd1905. PMID 16341062. S2CID 13270787.
Boot JD, de Haas S, Tarasevych S, et al. (March 2007). "Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma". Am. J. Respir. Crit. Care Med. 175 (5): 450–7. doi:10.1164/rccm.200608-1186OC. PMID 17170385. S2CID 22707433.
Navari RM (December 2007). "Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting". Expert Opin Investig Drugs. 16 (12): 1977–85. doi:10.1517/13543784.16.12.1977. PMID 18042005. S2CID 21437603.